Determination of oxidative stress parameters in fluoxetine users

Magda Susana Perassolo; Juliana Raquel Raach; Tainara  gomes Vargas; Andressa Schmidt dos Santos; Natália Alves Silva; Roberta Ziles Hahn; Ana Luiza Ziulkoski; Rafael Linden; Andresa Heemann Betti

doi:10.31686/ijier.vol8.iss5.2328

Authors

Magda Susana Perassolo a:1:{s:5:"en_US";s:18:"Feevale University";}
Juliana Raquel Raach Feevale University
Tainara gomes Vargas Feevale University
Andressa Schmidt dos Santos Feevale University
Natália Alves Silva Feevale University
Roberta Ziles Hahn Feevale University
Ana Luiza Ziulkoski Feevale University
Rafael Linden Feevale University
Andresa Heemann Betti Feevale University

DOI:

https://doi.org/10.31686/ijier.vol8.iss5.2328

Keywords:

antioxidants, fluoxetine, reactive oxygen species, oxidative stress, major depression

Abstract

Fluoxetine (FLU), a selective serotonin reuptake inhibitor, is the first line in depression treatment and it is involved in oxidative stress (OE). Thus, this study aimed to analyze the OE parameters in patients diagnosed with depression and treated with FLU. Were evaluated 121 volunteers divided into two groups: 58 fluoxetine users (with major depression) and 63 non-fluoxetine users (control group, without major depression). The OE was evaluated by determining the levels of malondialdehyde (MDA), total antioxidant power (FRAP) and activity of antioxidant enzymes glutathione peroxidase (GPx) and superoxide dismutase (SOD). MDA, FRAP, GPx and SOD were dosed in plasma. The influence of age, smoking, alcoholism, comorbidities, use of another drugs and antioxidants in the OE were evaluated. The results were compared between the groups. In relation to the fluoxetine daily dose, MDA presented higher levels in patients using 20 mg daily FLU when compared to the control group, as well as the activity of the GPx enzyme and the FRAP levels. In this way, the use of fluoxetine may interfere with the OE parameters, causing an increase in OE levels.

Downloads

Download data is not yet available.

References

R.C Kessler, K.A. Mcgonagle, S. Zhao, C.B Nelson, M. Hughes, S. Eshleman, H. Wittchen and K.S. Kendler, Lifetime and Annu, Rev Public Health, 2013, 34:119–38.

B.J. Rawdin, S.H. Mellon, F.S. Dhabhar, E.S. Epel, E. Puterman, Y. Su, H.M. Burke, V.I. Reus, R. Rosser, S.P. Hamilton, J.C. Nelson and O.M. Wolkowitz, Dysregulated relationship of inﬂammation and oxidative stress in major depression, Brain Behav Immun, 2013, 31:143–52. DOI: https://doi.org/10.1016/j.bbi.2012.11.011

M. Luca, A. Luca and C. Calandra, Accelerated aging in major depression: the role of nitro-oxidative stress, Oxi Med Cell Longev, 2013, Article ID 230797, 6 pages. DOI: https://doi.org/10.1155/2013/230797

O. Deger, M. Bekaroglu, A. Orem., S. Orem and N. Uluutku, Major depression and activation of the inflammatory response system C, Cytokines, Stress, and Depression, 1999, 461:25-46. DOI: https://doi.org/10.1007/978-0-585-37970-8_2

M. Maes, J. Lambrechts, E. Bosmans, J. Jacobs, E. Suy, C. Vandervorst, C. de-Jonckheere, M. Minner and J. Raus, Evidence for a systemic immune activation during depression, of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining, Psychol Med. 1992, 22:45–53. DOI: https://doi.org/10.1017/S0033291700032712

G. Grases, M.A. Colom, P. Sanchis and F. Grases, Possible relation between consumption of different food groups and depression, Psychology, 2019: 7:14. DOI: https://doi.org/10.1186/s40359-019-0292-1

C.P. Chung, D. Schmidt, C.M Stein, J.D. Morrow and R.M Salomon, Increased oxidative stress in patients with depression and its relationship to treatment, Psychiatry Res, 2013, 206:213–6. DOI: https://doi.org/10.1016/j.psychres.2012.10.018

A. Bajpai, A.K. Verma, M. Srivastava and R. Srivastava, Oxidative stress and major depression, J Clin Diagn Res, 2014, 8(12):CC04-7.

M. Maes, R. Yirmyia, J. Noraberg, S. Brene, J. Hibbeln, G. Perini, M. Kubera, P. Bob, B. Lerer and M. Maj, The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression, Metab Brain Dis, 2009, 24:27–53. DOI: https://doi.org/10.1007/s11011-008-9118-1

J. Li, O. Wuliji, W. Li, Z.G. Jiang and H.A. Ghanbari, Oxidative stress and neurodegenerative disorders, Int J Mol Sci, 2013, 14:24438-75. DOI: https://doi.org/10.3390/ijms141224438

M. Valko, D. Leibfritz, J. Moncol, M.T. Cronin, M. Mazur and J. Telser, Free radicals and antioxidants in normal physiological functions and human disease, Int J Biochem Cell Biol, 2007, 39:44–84. DOI: https://doi.org/10.1016/j.biocel.2006.07.001

P. Karihtala and Y. Soini, Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies, APMIS, 2007, 115:81–103. DOI: https://doi.org/10.1111/j.1600-0463.2007.apm_514.x

R.L. Prior and G. Cao, In vivo total antioxidant capacity: comparison of different analytical methods, Free Radical Biol Med,1999, 27:1173–81. DOI: https://doi.org/10.1016/S0891-5849(99)00203-8

E.S. Hwang and G.H. Kim, Biomarkers of oxidative stress status of DNA, lipids, and proteins in vitro and in vivo cancer research, Toxicology, 2007, 229:1–10. DOI: https://doi.org/10.1016/j.tox.2006.10.013

V. Caiaffo, B.D.R. Oliveira, F.B. de Sá and J. Evêncio Neto, Anti-inflammatory, antiapoptotic, and antioxidant activity of fluoxetine, Pharmacol Res Perspect, 2016, 4(3):e00231. DOI: https://doi.org/10.1002/prp2.231

H. Tsuboi, A. Tatsumi, K. Yamamoto, F. Kobayashi, K. Shimoi and N. Kinae, Possible connection among job stress, depressive symptoms, lipid modulation and antioxidants, J Affect Disord, 2006, 9:63–70. DOI: https://doi.org/10.1016/j.jad.2005.12.010

P. Galecki, J. Szemraj, M. Bienkiewicz, A. Florkowski and E. Galecka, Lipid peroxidation and antioxidante protection in patients during acute depressive episodes and in remission after fluoxetine treatment, Pharmacol Rep, 2009, 61:439–47. DOI: https://doi.org/10.1016/S1734-1140(09)70084-2

M. Bilici, H. Efe, A. Koroglu, H.A. Uydu, M. Bekaroglu and O. Deger, Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments, J Affect Disorder, 2001, 64:43–51. DOI: https://doi.org/10.1016/S0165-0327(00)00199-3

S.D. Khanzode, G.N. Dakhale, S.S. Khanzode, A. Saoji and R. Palasodkar, Oxidative damage and major depression: the potential antioxidant action of selective serotonin reuptake inhibitors, Redox Rep, 2003, 8:365–70. DOI: https://doi.org/10.1179/135100003225003393

H. Herken, A. Gurel , S. Selek, F. Armutcu, M. Ozen, M. Bulut, O. Kap, M. Yumru, H.A. Savas and O. Akyol, Adenosine deaminase, nitric oxide, superoxide dismutase, and xanthine oxidase in patients with major depression: Impact of antidepressant treatment, Arch Med Res, 2007, 38:247–52. DOI: https://doi.org/10.1016/j.arcmed.2006.10.005

A. Sarandol, E. Sarandol, S. Eker, S. Erdinc, E. Vatansever and S. Kirli, Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative system, Hum Psychopharmacol, 2007, 22:67–73. DOI: https://doi.org/10.1002/hup.829

M. Siwek, M. Sowa-Kućma, D. Dudek, K. Styczeń, B. Szewczyk, K. Kotarska, P. Misztakk, A. Pilc, M. Wolak and G. Nowak, Oxidative stress markers in affective disorders, Pharmacol Rep, 2013, 65:1558-71. DOI: https://doi.org/10.1016/S1734-1140(13)71517-2

M.E. Ozcan, M. Gulec, E. Ozerol, R. Polat and O. Akyol, Antioxidant enzyme activities and oxidative stress in affective disorders, Int Clin Psychopharmacol, 2004, 19(2):89–95. DOI: https://doi.org/10.1097/00004850-200403000-00006

O.M.E.A. Salam, N.A. Mohammed, A.A. Sleem and A.R. Farrag, The effect of antidepressant drugs on thioacetamide-induced oxidative stress, Eur Rev Med Pharmacol Sci, 2013, 17:735-44.

M.I. Wilde and P. Benfield, Fluoxetine: A pharmacoeconomic review of its use in depression, Pharmacoeconomics, 1998, 13:543–61. DOI: https://doi.org/10.2165/00019053-199813050-00007

S. Novio, M.J. Nunez, G. Amigo and M. Freire-Garabal, Effects of ﬂuoxetine on the oxidative status of peripheral blood leucocytes of restraintstressed mice, Basic Clin Pharmacol Toxicol, 2011, 109:365–71. DOI: https://doi.org/10.1111/j.1742-7843.2011.00736.x

A. Zaﬁr and N. Banu, Antioxidant potencial of ﬂuoxetine in comparison to Curcuma longa in restraint-stressed rats, Eur J Pharmacol, 2007, 572:23–31. DOI: https://doi.org/10.1016/j.ejphar.2007.05.062

N. Kolla, Z. Wei, J.S. Richardson and X.M Li, Amitriptyline and ﬂuoxetine protect PC2 cells from cell death induced by hydrogen peroxide, J Psychiatry Neurosci, 2005, 30:196–201.

M.V. Antunes, C. Lazzaretti, G.D. Gamaro and R. Linden, Estudo pré analítico e de validação para determinação de malondialdeído em plasma humano por cromatografia líquida de alta eficiência, após derivatização com 2,4-dinitrofenilhidrazina, RBCF, 2008, 44(2):279-87. DOI: https://doi.org/10.1590/S1516-93322008000200013

I.F.F. Benzie and J.J Strain, The ferric reducing ability of plasma (FRAP) as a measure of ‘‘Antioxidant Power’’: The FRAP Assay, Anal Biochem, 1996, 239:70–6. DOI: https://doi.org/10.1006/abio.1996.0292

P.A. Pleban, A. Munyani and J. Beachum, Determination of selenium concentration and glutathione peroxidase activity in plasma and erythrocytes, Clin Chem, 1982, 2:311-16 DOI: https://doi.org/10.1093/clinchem/28.2.311

J. Djordjevic, A. Djordjevic, M. Adzic, I. Elakovic, G. Matic and M.B Radojci, Fluoxetine affects antioxidant system and promotes apoptotic singnaling in Wistar rat liver, Eur J Parmacol, 2011, 659:61–6. DOI: https://doi.org/10.1016/j.ejphar.2011.03.003

J. Zlatkovic, N. Todorović, N. Tomanović, M. Bošković, S. Djordjević, T. Lazarević-Pašti, R.E. Bernardi, A. Djurdjević and D. Filipović, Chronic administration of ﬂuoxetine or clozapine induces oxidative stress in rat liver: a histopathological study, Eur J Pharm Sci, 2014, 59:20–30. DOI: https://doi.org/10.1016/j.ejps.2014.04.010

D. Belowski, J. Kowalski, A. Madej and Z. Herman, Influence of antidepressant drugs on macrophage cytotoxic activity in rats, Pol J Pharmacol, 2004, 56:837–42.